184 related articles for article (PubMed ID: 34453638)
1. Oestrogen-regulated protein SLC39A6: a biomarker of good prognosis in luminal breast cancer.
Althobiti M; El-Sharawy KA; Joseph C; Aleskandarany M; Toss MS; Green AR; Rakha EA
Breast Cancer Res Treat; 2021 Oct; 189(3):621-630. PubMed ID: 34453638
[TBL] [Abstract][Full Text] [Related]
2. The solute carrier SLC7A8 is a marker of favourable prognosis in ER-positive low proliferative invasive breast cancer.
El Ansari R; Alfarsi L; Craze ML; Masisi BK; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2020 May; 181(1):1-12. PubMed ID: 32200487
[TBL] [Abstract][Full Text] [Related]
3. Mediator complex (MED) 7: a biomarker associated with good prognosis in invasive breast cancer, especially ER+ luminal subtypes.
Joseph C; Macnamara O; Craze M; Russell R; Provenzano E; Nolan CC; Diez-Rodriguez M; Sonbul SN; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Mukherjee A
Br J Cancer; 2018 Apr; 118(8):1142-1151. PubMed ID: 29588513
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis.
Aleskandarany MA; Abduljabbar R; Ashankyty I; Elmouna A; Jerjees D; Ali S; Buluwela L; Diez-Rodriguez M; Caldas C; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Sep; 159(2):215-27. PubMed ID: 27514395
[TBL] [Abstract][Full Text] [Related]
5. Kinesin family member-18A (KIF18A) is a predictive biomarker of poor benefit from endocrine therapy in early ER+ breast cancer.
Alfarsi LH; Elansari R; Toss MS; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Jan; 173(1):93-102. PubMed ID: 30306428
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of BMI1 expression in invasive breast cancer is dependent on its molecular subtypes.
Althobiti M; Muftah AA; Aleskandarany MA; Joseph C; Toss MS; Green A; Rakha E
Breast Cancer Res Treat; 2020 Aug; 182(3):581-589. PubMed ID: 32524353
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.
Habashy HO; Powe DG; Rakha EA; Ball G; Macmillan RD; Green AR; Ellis IO
Breast Cancer Res Treat; 2010 Apr; 120(3):603-12. PubMed ID: 19495959
[TBL] [Abstract][Full Text] [Related]
8. The amino acid transporter SLC7A5 confers a poor prognosis in the highly proliferative breast cancer subtypes and is a key therapeutic target in luminal B tumours.
El Ansari R; Craze ML; Miligy I; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res; 2018 Mar; 20(1):21. PubMed ID: 29566741
[TBL] [Abstract][Full Text] [Related]
9. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
10. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy.
Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and biological significance of peroxisome proliferator-activated receptor-gamma in luminal breast cancer.
Abduljabbar R; Al-Kaabi MM; Negm OH; Jerjees D; Muftah AA; Mukherjee A; Lai CF; Buluwela L; Ali S; Tighe PJ; Green A; Ellis I; Rakha E
Breast Cancer Res Treat; 2015 Apr; 150(3):511-22. PubMed ID: 25794775
[TBL] [Abstract][Full Text] [Related]
12. DACH1: its role as a classifier of long term good prognosis in luminal breast cancer.
Powe DG; Dhondalay GK; Lemetre C; Allen T; Habashy HO; Ellis IO; Rees R; Ball GR
PLoS One; 2014; 9(1):e84428. PubMed ID: 24392136
[TBL] [Abstract][Full Text] [Related]
13. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.
Thorat MA; Marchio C; Morimiya A; Savage K; Nakshatri H; Reis-Filho JS; Badve S
J Clin Pathol; 2008 Mar; 61(3):327-32. PubMed ID: 18037662
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the prognostic significance of solute carrier (SLC) family 39 genes in breast cancer.
Liu L; Yang J; Wang C
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32744318
[TBL] [Abstract][Full Text] [Related]
15. SLC39A6: a potential target for diagnosis and therapy of esophageal carcinoma.
Cui XB; Shen YY; Jin TT; Li S; Li TT; Zhang SM; Peng H; Liu CX; Li SG; Yang L; Li N; Hu JM; Jiang JF; Li M; Liang WH; Li Y; Wei YT; Sun ZZ; Wu CY; Chen YZ; Li F
J Transl Med; 2015 Oct; 13():321. PubMed ID: 26444413
[TBL] [Abstract][Full Text] [Related]
16. The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer.
El-Ansari R; Craze ML; Alfarsi L; Soria D; Diez-Rodriguez M; Nolan CC; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2019 May; 175(1):27-38. PubMed ID: 30671766
[TBL] [Abstract][Full Text] [Related]
17. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
[TBL] [Abstract][Full Text] [Related]
18. Expression of FOXA1 and GATA-3 in breast cancer: the prognostic significance in hormone receptor-negative tumours.
Albergaria A; Paredes J; Sousa B; Milanezi F; Carneiro V; Bastos J; Costa S; Vieira D; Lopes N; Lam EW; Lunet N; Schmitt F
Breast Cancer Res; 2009; 11(3):R40. PubMed ID: 19549328
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of STAT3 in invasive breast cancer: analysis of protein and mRNA expressions in large cohorts.
Aleskandarany MA; Agarwal D; Negm OH; Ball G; Elmouna A; Ashankyty I; Nuglozeh E; Fazaludeen MF; Diez-Rodriguez M; Nolan CC; Tighe PJ; Green AR; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2016 Feb; 156(1):9-20. PubMed ID: 26907764
[TBL] [Abstract][Full Text] [Related]
20. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
